TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Oropharyngeal Exercises on Snoring Intensity, Symptoms, Upper Airway Anatomy and Collapsability of Upper Airway Awake and Asleep in Patients With Primary Snoring and Mild to Moderate Obstructive Sleep Apnea
Brief Summary: Randomized study of patients with primary snore, mild and moderate obstructive sleep apnea. Protocol include 40 patients randomized to oropharyngeal exercise or use of nasal dilator, breathing exercise and nasal lavage. The objectives are study the effects of therapy on oropharyngeal in a series of clinical and physiologic and anatomic variables, changes on snore and quality of sleep using Pharyngeal Critical Pressure, Magnetic Resonance, Negative expiratory pressure and snore analyses. Hypothesis that the therapy group (oropharyngeal exercises) will have more modifications compared to the control group.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Smart phone game play | Intervention Type: OTHER; Name: Smart phone game play; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: placebo exercices; Type: PLACEBO_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Arm Label: phonoaudiologic therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): phonoaudiologic therapy, placebo exercices
C: Arm Label: 1; Type: SHAM_COMPARATOR; Interventions: Behavioral: Deep breathing, bilateral alternate chewing, nasal lavage | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Oropharyngeal exercises | Intervention Type: BEHAVIORAL; Name: Deep breathing, bilateral alternate chewing, nasal lavage; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Oropharyngeal exercises; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Oropharyngeal exercises | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Behavioral: Respiratory exercises, nasal dilator, nasal lavage | Intervention Type: BEHAVIORAL; Name: Oropharyngeal exercises; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Respiratory exercises, nasal dilator, nasal lavage; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NORADRENALINE VERSUS TERLIPRESSIN IN THE TREATMENT OF TYPE 2 HEPATORENAL SYNDROME:A RANDOMIZED STUDY
Brief Summary: Various vasoconstrictors have shown promising results in the management of type 1 hepatorenal syndrome (HRS). However, there are very few studies on vasopressors in the management of type 2 HRS. Terlipressin has been used commonly; however it is costly and not available in some countries. In the present study, the investigators evaluated safety and efficacy of terlipressin and noradrenaline in the treatment of type 2 HRS


Options:
A: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Terlipressin and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Arm Label: Noradrenaline and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Intervention Type: DRUG; Name: Noradrenaline; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NORADRENALINE VERSUS TERLIPRESSIN IN THE TREATMENT OF TYPE 2 HEPATORENAL SYNDROME:A RANDOMIZED STUDY
Brief Summary: Various vasoconstrictors have shown promising results in the management of type 1 hepatorenal syndrome (HRS). However, there are very few studies on vasopressors in the management of type 2 HRS. Terlipressin has been used commonly; however it is costly and not available in some countries. In the present study, the investigators evaluated safety and efficacy of terlipressin and noradrenaline in the treatment of type 2 HRS


Options:
A: Arm Label: Terlipressin and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Arm Label: Noradrenaline and Type-2 HRS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Noradrenaline, Drug: Terlipressin | Intervention Type: DRUG; Name: Noradrenaline; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Noradrenaline and Type-2 HRS, Terlipressin and Type-2 HRS
B: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: Terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Terlipressin; Type: EXPERIMENTAL; Interventions: Drug: terlipressin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: terlipressin; Assigned to Arm(s): Terlipressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Terlipressin | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Noradrenalin | Intervention Type: DRUG; Name: Terlipressin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Noradrenalin; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre Randomised Double Blinded Phase III Trial of the Effect of Standard Issue Red Blood Cell Blood Units on Mortality Compared to Freshest Available Red Blood Cell Units
Brief Summary: In Australia, blood for transfusion has a "use by" date of 42 days after collection. The actual age of blood given to patients depends on what is available at the time and the rate of usage. During the last decade, it has been reported that blood transfusion in patients admitted to intensive care was associated with an independent increase of mortality. Some research suggests that transfusion of fresher blood might help patients in the intensive care unit to reach a better recovery. This project will test whether patients who receive 'fresher' blood do better than patients who receive 'standard issue' blood.


Options:
A: Arm Label: Fresh not-leukocyte-reduced RBCs; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Arm Label: Fresh RBCs leukocyte-reduced; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Arm Label: RBCs with storage longer than 15 days; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood transfusion | Intervention Type: BIOLOGICAL; Name: Blood transfusion; Assigned to Arm(s): Fresh RBCs leukocyte-reduced, Fresh not-leukocyte-reduced RBCs, RBCs with storage longer than 15 days
B: Arm Label: Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Blood transfusion | Arm Label: Arm B; Type: OTHER; Interventions: Other: Blood transfusion | Intervention Type: OTHER; Name: Blood transfusion; Assigned to Arm(s): Arm B, Standard of care
C: Arm Label: Prolonged RBC storage; Type: ACTIVE_COMPARATOR; Interventions: Biological: Prolonged RBC storage | Arm Label: Short RBC storage; Type: ACTIVE_COMPARATOR; Interventions: Biological: Short RBC storage | Intervention Type: BIOLOGICAL; Name: Prolonged RBC storage; Assigned to Arm(s): Prolonged RBC storage | Intervention Type: BIOLOGICAL; Name: Short RBC storage; Assigned to Arm(s): Short RBC storage
D: Arm Label: Fresh blood, then aged blood; Type: EXPERIMENTAL; Interventions: Biological: Fresh blood, Biological: Aged blood | Intervention Type: BIOLOGICAL; Name: Fresh blood; Assigned to Arm(s): Fresh blood, then aged blood | Intervention Type: BIOLOGICAL; Name: Aged blood; Assigned to Arm(s): Fresh blood, then aged blood

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre Randomised Double Blinded Phase III Trial of the Effect of Standard Issue Red Blood Cell Blood Units on Mortality Compared to Freshest Available Red Blood Cell Units
Brief Summary: In Australia, blood for transfusion has a "use by" date of 42 days after collection. The actual age of blood given to patients depends on what is available at the time and the rate of usage. During the last decade, it has been reported that blood transfusion in patients admitted to intensive care was associated with an independent increase of mortality. Some research suggests that transfusion of fresher blood might help patients in the intensive care unit to reach a better recovery. This project will test whether patients who receive 'fresher' blood do better than patients who receive 'standard issue' blood.


Options:
A: Arm Label: Biological; Type: EXPERIMENTAL; Interventions: Biological: Transfusion | Arm Label: Standard PRBCs; Type: EXPERIMENTAL; Interventions: Biological: Transfusion | Intervention Type: BIOLOGICAL; Name: Transfusion; Assigned to Arm(s): Biological, Standard PRBCs
B: Arm Label: ARM A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Two packed red blood cells Transfusion | Arm Label: ARM B; Type: EXPERIMENTAL; Interventions: Drug: Single red blood packed cells Transfusion | Intervention Type: DRUG; Name: Single red blood packed cells Transfusion; Assigned to Arm(s): ARM B | Intervention Type: DRUG; Name: Two packed red blood cells Transfusion; Assigned to Arm(s): ARM A
C: Arm Label: Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Blood transfusion | Arm Label: Arm B; Type: OTHER; Interventions: Other: Blood transfusion | Intervention Type: OTHER; Name: Blood transfusion; Assigned to Arm(s): Arm B, Standard of care
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of 5 days or less storage age | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of conventional storage age | Intervention Type: OTHER; Name: RBC transfusion of 5 days or less storage age; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: RBC transfusion of conventional storage age; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre Randomised Double Blinded Phase III Trial of the Effect of Standard Issue Red Blood Cell Blood Units on Mortality Compared to Freshest Available Red Blood Cell Units
Brief Summary: In Australia, blood for transfusion has a "use by" date of 42 days after collection. The actual age of blood given to patients depends on what is available at the time and the rate of usage. During the last decade, it has been reported that blood transfusion in patients admitted to intensive care was associated with an independent increase of mortality. Some research suggests that transfusion of fresher blood might help patients in the intensive care unit to reach a better recovery. This project will test whether patients who receive 'fresher' blood do better than patients who receive 'standard issue' blood.


Options:
A: Arm Label: "liberal" transfusion triggers; Type: EXPERIMENTAL; Interventions: Other: red blood cell transfusion | Arm Label: "restrictive" transfusion triggers; Type: ACTIVE_COMPARATOR; Interventions: Other: red blood cell transfusion | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "liberal" transfusion triggers | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "restrictive" transfusion triggers
B: Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Biological: Administration of Red Cell | Arm Label: Liberal; Type: ACTIVE_COMPARATOR; Interventions: Biological: Administration of Red Cell | Intervention Type: BIOLOGICAL; Name: Administration of Red Cell; Assigned to Arm(s): Liberal, Restrictive
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion with Red Blood Cells, Biological: 1 unit of donated red blood cells | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: 1 unit of donated red blood cells | Intervention Type: PROCEDURE; Name: Transfusion with Red Blood Cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: 1 unit of donated red blood cells; Assigned to Arm(s): 2
D: Arm Label: Standard of care; Type: ACTIVE_COMPARATOR; Interventions: Other: Blood transfusion | Arm Label: Arm B; Type: OTHER; Interventions: Other: Blood transfusion | Intervention Type: OTHER; Name: Blood transfusion; Assigned to Arm(s): Arm B, Standard of care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Safety of REGN668 Administered Concomitantly With Topical Corticosteroids to Patients With Moderate-to-Severe Atopic Dermatitis
Brief Summary: The purpose of this study was to assess the safety of Dupilumab administered concomitantly with topical corticosteroids (TCS) in patients with moderate-to-severe atopic dermatitis (AD).


Options:
A: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Other: Background treatment | Arm Label: Dupilumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Background treatment | Arm Label: Dupilumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Background treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 150 mg, Dupilumab 300 mg | Intervention Type: OTHER; Name: Background treatment; Assigned to Arm(s): Dupilumab 150 mg, Dupilumab 300 mg, Placebo
B: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Other: Background treatment | Arm Label: Dupilumab 200 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Background treatment | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 200 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo qw | Intervention Type: OTHER; Name: Background treatment; Assigned to Arm(s): Dupilumab 200 mg qw, Placebo qw
C: Arm Label: Placebo QW; Type: EXPERIMENTAL; Interventions: Drug: Placebo (for Dupilumab), Other: Topical Corticosteroid (TCS) | Arm Label: Dupilumab 300 mg QW; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Topical Corticosteroid (TCS) | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg QW | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Placebo QW | Intervention Type: OTHER; Name: Topical Corticosteroid (TCS); Assigned to Arm(s): Dupilumab 300 mg QW, Placebo QW
D: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 100 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo qw

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 4 Study of Optimal Dose of Haloperidol
Brief Summary: Low-dose haloperidol is known to be effective for the treatment of postoperative nausea and vomiting (PONV). However, precise dose-response studies have not been completed, especially in patients at high risk for PONV who require combination therapy. This study sought to identify the optimal dose of haloperidol that could be combined with dexamethasone without adverse effects in high-risk PONV patients receiving intravenous patient-controlled anesthesia (IV PCA) after gynecological laparoscopic surgery.


Options:
A: Intervention Type: DRUG; Name: MK0869, aprepitant; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: ondansetron IV; Assigned to Arm(s): N/A
B: Arm Label: Treatment A:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Treatment B:; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone, Drug: Placebos | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Treatment A:, Treatment B: | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo, Treatment B:
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW679769 (casopitant) | Intervention Type: DRUG; Name: GW679769 (casopitant); Assigned to Arm(s): Arm 1
D: Arm Label: dexamethasone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dexamethasone iv injection | Arm Label: dexamethasone, haloperiol 1mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone, haloperidol | Arm Label: dexamethasone + haloperidol 2mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone, haloperidol | Intervention Type: DRUG; Name: Dexamethasone iv injection; Assigned to Arm(s): dexamethasone | Intervention Type: DRUG; Name: Dexamethasone, haloperidol; Assigned to Arm(s): dexamethasone, haloperiol 1mg | Intervention Type: DRUG; Name: Dexamethasone, haloperidol; Assigned to Arm(s): dexamethasone + haloperidol 2mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lumbar Segmental Stabilization and TENS in Lumbar Disc Herniation: a Randomized Clinical Trial
Brief Summary: The purpose of this study was to compare the efficacy of method Lumbar Segmental Stabilization and transcutaneous electrical nerve stimulation (TENS) on pain, functional disability and ability to activate the transversus abdominis (TrA) of individuals with chronic back pain caused by disc herniation.


Options:
A: Arm Label: Pilates 1; Type: EXPERIMENTAL; Interventions: Device: Pilates 1 | Arm Label: Pilates 2; Type: EXPERIMENTAL; Interventions: Device: Pilates 2 | Arm Label: Pilates 3; Type: EXPERIMENTAL; Interventions: Device: Pilates 3 | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Control | Intervention Type: DEVICE; Name: Pilates 1; Assigned to Arm(s): Pilates 1 | Intervention Type: DEVICE; Name: Pilates 2; Assigned to Arm(s): Pilates 2 | Intervention Type: DEVICE; Name: Pilates 3; Assigned to Arm(s): Pilates 3 | Intervention Type: DEVICE; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Physical Activity Only; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity | Arm Label: Physical Activity + Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity, Behavioral: Cognitive Behavioral Therapy | Arm Label: Wait List Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity + Cognitive Behavioral Therapy, Physical Activity Only | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Physical Activity + Cognitive Behavioral Therapy
C: Arm Label: Lumbar stabilization exercises; Type: EXPERIMENTAL; Interventions: Other: Lumbar stabilization exercises | Arm Label: TENS group; Type: EXPERIMENTAL; Interventions: Other: Lumbar stabilization exercises | Intervention Type: OTHER; Name: Lumbar stabilization exercises; Assigned to Arm(s): Lumbar stabilization exercises, TENS group
D: Arm Label: Sensorimotor; Type: EXPERIMENTAL; Interventions: Other: Proprioceptive postural training, Other: Conventional physiotherapy | Arm Label: Low-intensity activity; Type: ACTIVE_COMPARATOR; Interventions: Other: Treadmill training, Other: Conventional physiotherapy | Intervention Type: OTHER; Name: Proprioceptive postural training; Assigned to Arm(s): Sensorimotor | Intervention Type: OTHER; Name: Treadmill training; Assigned to Arm(s): Low-intensity activity | Intervention Type: OTHER; Name: Conventional physiotherapy; Assigned to Arm(s): Low-intensity activity, Sensorimotor

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hypofractionated Ion Irradiation (Carbon Ions Versus Protons) of the Prostate
Brief Summary: The purpose of this study is to evaluate the safety and feasibility of primary hypofractionated irradiation of the prostate with carbon ions or protons using the raster scan technique.


Options:
A: Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Radiation: 45 Gy/25 fractions | Arm Label: Arm A Control; Type: OTHER; Interventions: Radiation: 45 Gy/25 fractions | Intervention Type: RADIATION; Name: 45 Gy/25 fractions; Assigned to Arm(s): Arm A Control, Arm B
B: Arm Label: protons; Type: EXPERIMENTAL; Interventions: Procedure: radiation | Arm Label: carbon ions; Type: EXPERIMENTAL; Interventions: Procedure: radiation | Intervention Type: PROCEDURE; Name: radiation; Assigned to Arm(s): carbon ions, protons
C: Arm Label: Group A: Verum Acupuncture; Type: EXPERIMENTAL; Interventions: Radiation: Radiotherapy, Device: Needle Acupuncture | Arm Label: Group B: Sham Acupuncture; Type: SHAM_COMPARATOR; Interventions: Radiation: Radiotherapy, Device: Needle Acupuncture | Intervention Type: RADIATION; Name: Radiotherapy; Assigned to Arm(s): Group A: Verum Acupuncture, Group B: Sham Acupuncture | Intervention Type: DEVICE; Name: Needle Acupuncture; Assigned to Arm(s): Group A: Verum Acupuncture, Group B: Sham Acupuncture
D: Arm Label: Arm Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Arm Soy Supplement; Type: EXPERIMENTAL; Interventions: Drug: Soy Supplement | Intervention Type: DRUG; Name: Soy Supplement; Assigned to Arm(s): Arm Soy Supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm Placebo

Answer: B